Clinical trials
Prediabetic State trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 6 |
| 2025 | 8 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 15 |
| Completed | 13 |
| Recruiting | 10 |
| Not yet recruiting | 6 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shandong Provincial Hospital | 3 |
| China-Japan Friendship Hospital | 2 |
| Eli Lilly and Company | 2 |
| Shanghai 6th People's Hospital | 2 |
| Société des Produits Nestlé (SPN) | 2 |
| Amway (China) R&D Center | 1 |
| Beijing Anzhen Hospital | 1 |
| Beijing Tsinghua Chang Gung Hospital | 1 |
| Beijing University of Chinese Medicine | 1 |
| China National Center for Cardiovascular Diseases | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prediabetic State | 47 |
| Obesity | 14 |
| Glucose Intolerance | 8 |
| Overweight | 7 |
| Diabetes Mellitus | 5 |
| Insulin Resistance | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Dyslipidemias | 3 |
| Obesity, Abdominal | 3 |
| Cardiovascular Diseases | 2 |
Trials
Showing 26 to 47 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.